Literature DB >> 31599942

Murine Model of Maternal Immunization Demonstrates Protective Role for Antibodies That Mediate Antibody-Dependent Cellular Cytotoxicity in Protecting Neonates From Herpes Simplex Virus Type 1 and Type 2.

Carol M Kao1, Jessica Goymer2, Lip Nam Loh2, Aakash Mahant2, Clare Burn Aschner2, Betsy C Herold1,2.   

Abstract

BACKGROUND: Neonatal herpes simplex virus (HSV) disease results in unacceptable morbidity and mortality. The primary humoral immune response to natural infection is neutralizing antibodies (Abs). However, Abs that activate Fc gama receptors (FcγRs) and mediate antibody-dependent cell-mediated cytotoxicity (ADCC) may play a dominant role in protection. In adult mice, a single-cycle HSV candidate vaccine deleted in glycoprotein-D (ΔgD-2) that induces ADCC provided complete protection against HSV disease and prevented the establishment of latency. Passive transfer studies showed that Abs were sufficient for protection. The current study tested the hypothesis that maternal immunization with ΔgD-2 would protect neonates.
METHODS: C57BL/6 female mice were vaccinated 3 weeks apart with ΔgD-2, and pups were challenged at different times postnatally with lethal doses of HSV-1 or HSV-2. Concentration and functionality of Abs and immune cells were assessed.
RESULTS: Maternal ΔgD-2 immunization provided significant protection and reduced viral dissemination after lethal challenge with HSV-1 or HSV-2. Protection correlated with Abs acquired transplacentally or from breastmilk that mediated ADCC. Protection was reduced when pups were challenged on Day 1 of life, and this was associated with decreased ability of newborn cells to mediate Ab-dependent cell killing.
CONCLUSIONS: Antibodies mediating ADCC provide significant protection against neonatal HSV.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  antibody-dependent cellular cytotoxicity; HSV vaccines; neonatal herpes

Mesh:

Substances:

Year:  2020        PMID: 31599942      PMCID: PMC7768689          DOI: 10.1093/infdis/jiz521

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   7.759


  34 in total

Review 1.  Neonatal adaptive immunity comes of age.

Authors:  Becky Adkins; Claude Leclerc; Stuart Marshall-Clarke
Journal:  Nat Rev Immunol       Date:  2004-07       Impact factor: 53.106

Review 2.  Role of antibody-dependent cellular cytotoxicity in neonatal infection with herpes simplex virus.

Authors:  S Kohl
Journal:  Rev Infect Dis       Date:  1991 Nov-Dec

3.  Maternal immunization confers protection against neonatal herpes simplex mortality and behavioral morbidity.

Authors:  Chaya D Patel; Iara M Backes; Sean A Taylor; Yike Jiang; Arnaud Marchant; Jean M Pesola; Donald M Coen; David M Knipe; Margaret E Ackerman; David A Leib
Journal:  Sci Transl Med       Date:  2019-04-10       Impact factor: 17.956

4.  Characterization of natural killer and antibody-dependent cellular cytotoxicity of preterm infants against human immunodeficiency virus-infected cells.

Authors:  J D Merrill; M Sigaroudinia; S Kohl
Journal:  Pediatr Res       Date:  1996-09       Impact factor: 3.756

5.  The acquisition of herpes simplex virus during pregnancy.

Authors:  Z A Brown; S Selke; J Zeh; J Kopelman; A Maslow; R L Ashley; D H Watts; S Berry; M Herd; L Corey
Journal:  N Engl J Med       Date:  1997-08-21       Impact factor: 91.245

Review 6.  The neonatal human's immune response to herpes simplex virus infection: a critical review.

Authors:  S Kohl
Journal:  Pediatr Infect Dis J       Date:  1989-02       Impact factor: 2.129

7.  Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults: a double-blind randomized trial.

Authors:  Geert Leroux-Roels; Frédéric Clément; Pierre Vandepapelière; Marc Fourneau; Thomas C Heineman; Gary Dubin
Journal:  Hum Vaccin Immunother       Date:  2013-02-22       Impact factor: 3.452

8.  Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease.

Authors:  Christopher Petro; Pablo A González; Natalia Cheshenko; Thomas Jandl; Nazanin Khajoueinejad; Angèle Bénard; Mayami Sengupta; Betsy C Herold; William R Jacobs
Journal:  Elife       Date:  2015-03-10       Impact factor: 8.140

9.  Polyclonal HIV envelope-specific breast milk antibodies limit founder SHIV acquisition and cell-associated virus loads in infant rhesus monkeys.

Authors:  Jonathon E Himes; Ria Goswami; Riley J Mangan; Amit Kumar; Thomas L Jeffries; Joshua A Eudailey; Holly Heimsath; Quang N Nguyen; Justin Pollara; Celia LaBranche; Meng Chen; Nathan A Vandergrift; James W Peacock; Faith Schiro; Cecily Midkiff; Guido Ferrari; David C Montefiori; Xavier Alvarez Hernandez; Pyone Pyone Aye; Sallie R Permar
Journal:  Mucosal Immunol       Date:  2018-08-16       Impact factor: 8.701

10.  First estimates of the global and regional incidence of neonatal herpes infection.

Authors:  Katharine J Looker; Amalia S Magaret; Margaret T May; Katherine M E Turner; Peter Vickerman; Lori M Newman; Sami L Gottlieb
Journal:  Lancet Glob Health       Date:  2017-01-31       Impact factor: 26.763

View more
  13 in total

1.  Trivalent Glycoprotein Subunit Vaccine Prevents Neonatal Herpes Simplex Virus Mortality and Morbidity.

Authors:  Chaya D Patel; Sean A Taylor; Jesse Mehrbach; Sita Awasthi; Harvey M Friedman; David A Leib
Journal:  J Virol       Date:  2020-05-18       Impact factor: 5.103

Review 2.  Vaccines to prevent genital herpes.

Authors:  Kevin Egan; Lauren M Hook; Philip LaTourette; Angela Desmond; Sita Awasthi; Harvey M Friedman
Journal:  Transl Res       Date:  2020-03-16       Impact factor: 7.012

3.  Maternally transferred mAbs protect neonatal mice from HSV-induced mortality and morbidity.

Authors:  Iara M Backes; Brook K Byrd; Matthew D Slein; Chaya D Patel; Sean A Taylor; Callaghan R Garland; Scott W MacDonald; Alejandro B Balazs; Scott C Davis; Margaret E Ackerman; David A Leib
Journal:  J Exp Med       Date:  2022-09-26       Impact factor: 17.579

4.  A Single-Cycle Glycoprotein D Deletion Viral Vaccine Candidate, ΔgD-2, Elicits Polyfunctional Antibodies That Protect against Ocular Herpes Simplex Virus.

Authors:  Natalie L M Ramsey; Maria Visciano; Richard Hunte; Lip Nam Loh; Clare Burn Aschner; William R Jacobs; Betsy C Herold
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

5.  Vaccination Route as a Determinant of Protective Antibody Responses against Herpes Simplex Virus.

Authors:  Clare Burn Aschner; Carl Pierce; David M Knipe; Betsy C Herold
Journal:  Vaccines (Basel)       Date:  2020-06-05

Review 6.  Vaccines for Perinatal and Congenital Infections-How Close Are We?

Authors:  Tulika Singh; Claire E Otero; Katherine Li; Sarah M Valencia; Ashley N Nelson; Sallie R Permar
Journal:  Front Pediatr       Date:  2020-12-15       Impact factor: 3.418

Review 7.  Alphaherpesvirus Vaccines.

Authors:  Clare Burn Aschner; Betsy C Herold
Journal:  Curr Issues Mol Biol       Date:  2020-09-23       Impact factor: 2.081

8.  HVEM signaling promotes protective antibody-dependent cellular cytotoxicity (ADCC) vaccine responses to herpes simplex viruses.

Authors:  Clare Burn Aschner; Lip Nam Loh; Benjamin Galen; Isabel Delwel; Rohit K Jangra; Scott J Garforth; Kartik Chandran; Steven Almo; William R Jacobs; Carl F Ware; Betsy C Herold
Journal:  Sci Immunol       Date:  2020-08-14

Review 9.  Immune Response to Herpes Simplex Virus Infection and Vaccine Development.

Authors:  Anthony C Ike; Chisom J Onu; Chukwuebuka M Ononugbo; Eleazar E Reward; Sophia O Muo
Journal:  Vaccines (Basel)       Date:  2020-06-12

10.  Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine.

Authors:  Philip C LaTourette; Sita Awasthi; Angela Desmond; Norbert Pardi; Gary H Cohen; Drew Weissman; Harvey M Friedman
Journal:  Vaccine       Date:  2020-10-09       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.